Morgan Stanley
ACUR

Morgan Stanley’s Acura Pharmaceuticals ACUR Stock Holding History

Morgan Stanley’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,440
Closed -$1K – 6723
2016
Q4 		$1K Buy
1,440
+400
+38% +$418 ﹤0.01% 6497
2016
Q3 		$2K Sell
1,040
-16
-2% -$28 ﹤0.01% 6397
2016
Q2 		$2K Sell
1,056
-467
-31% -$1.21K ﹤0.01% 6397
2016
Q1 		$4K Buy
1,523
+1
+0.1% +$2 ﹤0.01% 6345
2015
Q4 		$4K Sell
1,522
-2,528
-62% -$6.15K ﹤0.01% 6435
2015
Q3 		$9K Buy
4,050
+2,531
+167% +$8.61K ﹤0.01% 6278
2015
Q2 		$7K Buy
1,519
+28
+2% +$116 ﹤0.01% 6386
2015
Q1 		$6K Hold
1,491
– – ﹤0.01% 6321
2014
Q4 		$3K Sell
1,491
-1,454
-49% -$4.02K ﹤0.01% 6416
2014
Q3 		$11K Sell
2,945
-740
-20% -$3.47K ﹤0.01% 6179
2014
Q2 		$20K Sell
3,685
-6,741
-65% -$40.9K ﹤0.01% 6035
2014
Q1 		$76K Buy
10,426
+5,152
+98% +$44.8K ﹤0.01% 5554
2013
Q4 		$44K Sell
5,274
-620
-11% -$5.24K ﹤0.01% 5640
2013
Q3 		$56K Sell
5,894
-22,866
-80% -$202K ﹤0.01% 5180
2013
Q2 		$270K Buy
+28,760
New +$325K ﹤0.01% 4663

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Morgan Stanley's ACUR Position: Q1 2017 in Review

Morgan Stanley sold out of Acura Pharmaceuticals (ACUR) in Q1 2017, closing a stake of 1,440 shares — an estimated $1K sold.

Morgan Stanley first reported a position in ACUR in Q2 2013 and held it in 15 quarters. The position peaked at $270K in Q2 2013. 3 funds tracked by Wall St. Rank hold ACUR as of Q1 2017.

  • Morgan Stanley reported no remaining Acura Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Morgan Stanley sold 1,440 Acura Pharmaceuticals shares in Q1 2017, an estimated $1K.
  • Morgan Stanley first reported a position in Acura Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Morgan Stanley's Acura Pharmaceuticals position peaked at $270K in Q2 2013.
  • 3 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q1 2017.

Based on Morgan Stanley's 13F filing for Q1 2017, filed 12 May 2017.